https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-02-25 / Cancer Immunol Immunother 2004 Jul;53(7):633-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-02-25 / Cancer Immunol Immunother 2004 Jul;53(7):633-412004-02-25 00:00:002023-03-07 13:15:18Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-01-01 / Int. J. Mol. Med. 2004 Jan;13(1):33-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-01-01 / Int. J. Mol. Med. 2004 Jan;13(1):33-92004-01-01 00:00:002019-02-15 08:53:30Thyroglobulin-pulsed human monocyte-derived dendritic cells induce CD4+ T cell activation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-01-01 / Breast Dis 2004;20:65-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-01-01 / Breast Dis 2004;20:65-712004-01-01 00:00:002004-01-01 00:00:00Dendritic cell-based therapeutics for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-01-01 / Cytotherapy 2004;6(2):154-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-01-01 / Cytotherapy 2004;6(2):154-632004-01-01 00:00:002019-02-15 08:50:27The immune response to breast cancer, and the case for DC immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-01-01 / Cytotherapy 2004;6(1):62-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-01-01 / Cytotherapy 2004;6(1):62-72004-01-01 00:00:002019-02-15 08:51:06DC-based immunotherapy of B-cell malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-12-01 / Leuk. Lymphoma 2003 Dec;44(12):2031-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-12-01 / Leuk. Lymphoma 2003 Dec;44(12):2031-82003-12-01 00:00:002019-02-15 08:51:25Dendritic cell-based immunotherapy in multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-12-01 / Hum. Cell 2003 Dec;16(4):175-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-12-01 / Hum. Cell 2003 Dec;16(4):175-822003-12-01 00:00:002019-02-15 08:46:08Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-15 / J. Clin. Oncol. 2003 Oct;21(20):3826-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-15 / J. Clin. Oncol. 2003 Oct;21(20):3826-352003-10-15 00:00:002019-02-15 08:49:35Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-06 / Br. J. Cancer 2003 Oct;89(7):1172-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-06 / Br. J. Cancer 2003 Oct;89(7):1172-92003-10-06 00:00:002019-02-15 08:47:01Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / Haematologica 2003 Oct;88(10):1139-49
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / Haematologica 2003 Oct;88(10):1139-492003-10-01 00:00:002019-02-15 08:51:07Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells
